

NOVAVAX INC  
Form 8-K  
August 22, 2013

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported):

**August 22, 2013**

---

**NOVAVAX, INC.**

(Exact Name of Registrant as Specified in Charter)

<b>Delaware</b>	<b>0-26770</b>	<b>22-2816046</b>
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

**9920 Belward Campus Drive**

**Rockville, Maryland 20850**

(Address of Principal Executive Offices)(Zip Code)

Registrant's telephone number, including area code: **(240) 268-2000**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 – Other Events.**

On August 22, 2013, Novavax, Inc. (the “Company”) announced its acceptance of all shares of Sweden-based Isconova AB (“Isconova”) tendered during the extended acceptance period for its public tender offer to acquire all outstanding shares and warrants of Isconova.

A copy of the Company’s press release announcing its acceptance of shares tendered during the extended acceptance period is filed herewith as Exhibit 99.1.

**(d) Exhibits.**

**Exhibit No. Description**

99.1 Press Release of Novavax, Inc. dated August 22, 2013.

2

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**NOVAVAX, INC.**

John A. Herrmann III, J.D.

Name: John A. Herrmann III, J.D.

Title: Vice President, General Counsel &  
Corporate Secretary

Date: August 22, 2013

**EXHIBIT INDEX**

**Exhibit No. Description**

99.1 Press Release of Novavax, Inc. dated August 22, 2013.